Genentech announces full FDA approval for Venclexta combinations for acute myeloid leukaemia
The approval is primarily based on the results of two Phase III studies, VIALE-A and VIALE-C
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.